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Lipophilic bismuth dimercaptopropanol nanoparticles (BisBAL NPs) have a very important antimicrobial activity; however
their effect on human cells or tissues has not been completely studied. Undesirable effects of bismuth include anemia which
could result from suicidal erythrocyte death or eryptosis. The objective of this research was to determine the effect of bismuth
dimercaptopropanol nanoparticles on blood cells. The nanoparticles are composed of 53 nm crystallites on average and have
a spherical structure, agglomerating into clusters of small nanoparticles. Based on cell viability assays and optical microscopy,
cytotoxicity on erythrocytes was observed after growing with 500 and 1000𝜇M of BisBAL NPs for 24 h. AM Calcein was retained
inside erythrocytes when they were exposed to 100 𝜇M (or lower concentrations) of BisBAL NPs for 24 h, suggesting the absence
of damage in plasmatic membrane. Genotoxic assays revealed no damage to genomic DNA of blood cells after 24 h of exposition
to BisBAL NPs. Finally, 100–1000𝜇M of bismuth nanoparticles promotes apoptosis between blood cells after 24 h of incubation.
Hence BisBAL NPs at concentrations lower than 100𝜇M do not cause damage on blood cells; they could potentially be used by
humans without affecting erythrocytes and leukocytes.
1. Introduction
Bismuth is used in industry and for treatment of gastro-
intestinal diseases [1, 2]. Previous reports described the very
interesting antimicrobial and antibiofilm properties of bis-
muth nanoparticles with significant potential to be used in
biomedical sciences [3–5]. Since elemental bismuth has very
low water solubility, it has been chelated with compounds
containing hydroxyl and sulfhydryl groups to produce water
soluble and biocompatible complexes that are employed in
pharmaceutical and personal care products (e.g., Pepto Bis-
mol, De-Nol, and Tirtec (Pylorid), catalysts, alloys, and pig-
ments) [6].
Early, the antimicrobial activity of nanostructures of sev-
eral metals like silver, gold, zinc, titanium, and bismuth has
been described with very good results [7–11]. However, most
of them present high toxicity on human cells, limiting their
use [12–15]. Several approaches were made to reduce the
undesired effects of metal nanoparticles; the most followed
one is adding a biocompatible cover of cellulose, chitosan, or
polymers like poly(lactic-co-glycolic acid) PLGA [16].
The toxicological aspects of bismuth compounds are well
established and the reported side effects may include neph-
ropathy, hepatitis, and encephalopathy [17]. Several stud-
ies described the absence of cytotoxicity of bismuth and
their compounds on human cells [18–20], and our group has
reported no cytotoxicity of 2mM bismuth oxide nanoparti-
cles on monkey kidney cells, after 24 hours of exposition [4].
The untoward effects of bismuth include anemia [21], which
could at least in theory result from stimulation of suicidal
erythrocyte death or eryptosis.
Eryptosis, the suicidal death of erythrocytes, is caused by
several anemia-inducing endogenous substances, diabetes,
chronic renal failure, hemolytic uremic syndrome, sepsis,
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malaria, iron deficiency, and exogenous substances [22]. Sev-
eral drugs have been described to trigger eryptosis, like
alantolactone, gramicidin, naphthazarin, nelfinavir, hemo-
lysin, listeriolysin, paclitaxel, chlorpromazine, cyclosporine,
methylglyoxal, amyloid peptides, anandamide, Bay-5884,
curcumin, valinomycin, aluminium, mercury, lead, and cop-
per [22–26]. Eryptosis is characterized by phosphatidylserine
exposure at the erythrocyte surface [27]. Phosphatidylserine
exposing erythrocytes are rapidly cleared from circulating
blood and result from phospholipid scrambling of the cell
membrane [28].
The objective of this work was to determine whether
BisBAL NPs trigger eryptosis in a cell culture. The effect of
BisBAL nanoparticles with an average diameter of 53 nm
and spherical shape was evaluated on blood cells. Based on
cell viability assays and optical microscopy, cytotoxicity on
erythrocytes was observed after growing with high concen-
trations (500–1000𝜇M) of BisBAL NPs for 24 h. This data
correlates with hemoglobin level of erythrocytes exposed to
the same concentrations of bismuth nanoparticles. Calcein
AMwas retained inside erythrocyteswhen theywere exposed
to 100 𝜇M (or lower concentrations) of BisBAL NPs for 24 h,
suggesting the absence of damage in plasmatic membrane of
host cells. Genotoxic assays revealed no damage to genomic
DNA of blood cells after 24 h of exposition to BisBAL NPs
and finally 500–1000𝜇M of bismuth nanoparticles promotes
apoptosis between blood cells after 24 h of incubation. All
together, these results suggest that ≤100 𝜇M of BisBAL NPs
does not present side effects on blood cells and could be used
in humans.
2. Material and Methods
2.1. Synthesis of BisBAL Nanoparticles. For the synthesis of
bismuth nanostructures, the following chemical reagents
were used: bismuth pentahydrate (Bi(NO
3
)
3
⋅5H
2
O), 2,3-
dimercapto-1-propanol (BAL), sodium borohydride (NaBH
4
),
and propylene glycol, which were all analytical grade reagents
purchased from Sigma-Aldrich (St. Louis, MO). Ultrapure
water (Barnstead Nanopure Diamond) was used to prepare
solutions and dilutions. BisBAL nanoparticles were synthe-
sized using a method that was described in our recent publi-
cations. A stock solution of 2 : 1 molar ratio of Bi (Bis) to 2,3-
dimercapto-1-propanol (BAL) (a.k.a. BisBAL) served as a
cationic precursor for the BisBAL nanoparticles and the
choice of molar ratio was based on the previous work, which
showed BisBAL was stable over a wide pH range (4–11) and
effective againstmicrobial biofilm formation [29]. During the
course of BisBAL reduction with NaBH
4
, the pink color of
soluble BisBAL instantly transformed to a black colored sus-
pension composed of BisBAL nanoparticles. The stock sus-
pensions of 25mM of BisBAL nanoparticles in 10mL batches
were prepared and stored at 4∘C until use.
2.2. Characterization of BisBAL Nanoparticles. The nanopar-
ticle size distribution was measured by dynamic light scat-
tering (DLS, ALV-GmbH, Germany, scattering angle set at
90∘). Information on the shape and size of nanoparticles
was obtained using scanning electron microscopy (SEM; FEI
Tecnai G2 Twin, Hillsboro, OR; 160 kV accelerating voltage).
Absorbance spectra of the nanoparticle suspensions were col-
lected using the UV-Visible spectrophotometer (SpectraMax
Plus384 Absorbance Microplate Reader, Molecular Devices,
LLC, Sunnyvale, CA). The rhombohedral crystallinity and
crystallite size were determined using the X-Ray Diffrac-
tometer (XRD: Panalytical X’Pert PROMRD) equipped with
Cu K𝛼 as X-ray source (𝜆 = 1.541874 A˚). Diffractograms were
interpreted using the Debye-Scherrer formula (Panalytical
X’Pert Data Viewer software) to estimate the rhombohedral
structure and crystallite size. The lipophilicity of BisBAL
nanoparticles was determined based on the affinity of nano-
particles to 1-octanol in 1-octanol-water phase mixture incu-
bated for 30 minutes. The absorbance of nanoparticles in a
phase was measured at 330 nm.
2.3. Blood Cells Culture and Their Quantification by MTT
Assay. From a blood sample without anticoagulant erythro-
cytes, neutrophils and leucocytes were collected and sepa-
rated by centrifugation at 14000 r.p.m. for 10 minutes [30].
After that, serum was retired from pellet of each fraction
and cells were washed three times with cold PBS 1x. Erythro-
cytes, neutrophils, and leucocytes were cultured inminimum
essential medium (MEM) supplemented with 10% of fetal
bovine serum, respectively (FBS, Biowest, Nuaille´, France),
onto 96-well plates (105/well for 24 h) in triplicate at 37∘C in a
humidified incubator containing 5% CO
2
. The cell viability
was evaluated by the amount of viable cells stained by 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(Biotium, Hayward, CA) which was released with dimethyl
sulfoxide (DMSO, Sigma-Aldrich Inc., St. Louis, MO, USA).
The optical density was detected at 595 nm using amicroplate
absorbance reader (Biotek, Winooski, VT). The killing effect
of bismuth nanoparticles on blood cells was calculated as cell
viability, which was indicated as follows: (the percentage of
viable cells) = (absorbance of treated wells − absorbance of
blank wells)/(absorbance of the control wells − absorbance of
blank wells) × 100%.
2.4. Influence of BisBAL NPs on Morphology of Erythrocytes
Culture by Optic Microscopy. From a blood sample without
anticoagulant, a monolayer of erythrocytes was obtained by
seeding 1 × 105 cells in a 96-well microtiter plate (Thermo
Fisher Scientific, MA, USA) in 100 𝜇L of minimum essential
medium (MEM) supplemented with 10% of fetal bovine
serum (FBS, Biowest, Nuaille´, France) and incubated at 37∘C
with 5% of CO
2
. 50, 100, 500, and 1000 𝜇M of BisBAL NPs
were added to cell culture and incubated for 1 hour at 37∘C
with 5% of CO
2
and their effect on cell morphology was
observed by opticalmicroscopy using an invertedmicroscope
(Motic, Hong Kong). The presence of cytopathic effect was
identified by amorphous shape, light refractive cells, and loss
of confluent monolayer.
2.5. Effect of BisBAL NPs on Blood Cells. The possible cyto-
toxicity of BisBAL NPs against erythrocytes, leukocytes, and
neutrophils was studied using the cell viability MTT [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
assay (Biotium, Hayward, CA) [31]. Following the protocol
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described above, 1 × 105 cells were incubated at 37∘C and 5%
of CO
2
overnight with 0, 5, 10, and 20𝜇M of BisBAL NPs
and free drug cells with culture medium alone as untreated
cells. After incubation, 10 𝜇L of MTT was added to each well
and incubated at 37∘C and 5% of CO
2
for 2 hours in dark
conditions, following which the medium was removed and
100 𝜇L of dimethyl sulfoxide (DMSO) was added to dissolve
the reduced MTT formazan product. The reduced MTT was
then assayed at 595 nm using a microplate absorbance reader
(Biotek, Winooski, VT) and DMSO was employed as blank.
The assay was done in triplicate and the measured optical
density was further analyzed by descriptive statistics.
2.6. Effect of BisBAL NPs on Hemoglobin Level. To analyze
the hypothesis if the addition of BisBAL NPs to a cell culture
could trigger erythrosis, the hemoglobin (Hb) levelwas deter-
mined by Coulter STKS [32] (Coulter Corporation, Hialeah,
FL, USA), following the instructions of provider. After 24 h
incubation, the nanoparticles solution was removed from cell
culture and washed three times with PBS 1x and the level of
Hb was measured. The assay was done in triplicate and the
measured concentration was further analyzed by descriptive
statistics.
2.7. Influence of Bismuth Nanoparticles on Plasmatic Mem-
brane of Erythrocytes by AM Calcein Assay and Fluorescence
Microscopy. Based on the protocol described above, the
influence of BisBAL NPs on erythrocytes was evaluated by
AM Calcein assay and fluorescence microscopy. After treat-
ment with 50–1000𝜇M of BisBAL NPs over 24 hours, cells
were washed three times with PBS and stained with AM Cal-
cein (Biotium, Hayward, CA) [33, 34]. The cytotoxicity and
integrity of cell membrane were interpreted as not Calcein
AM retained in the interior of cells with FITC filter at 485 nm
(Thornwood, NY).
2.8. BisBAL NPs on Genomic DNA of Erythrocytes by Comet
Assay. To determine the possible damage in genomic DNA
of erythrocytes after exposition to BisBAL NPs, Oxiselect
Comet Assay was employed (Cell Biolabs, Inc., CA, USA),
following the instructions of provider [35]. Briefly, erythro-
cytes were incubated at 37∘C and 5% of CO
2
overnight with
20𝜇M of BisBAL NPs or 10% H
2
O
2
(Sigma, SL., USA) as
positive control and free drug cells with culture medium
alone as untreated cells. After incubation, cells were collected
by centrifugation at 700×g for 2 minutes and discarding the
supernatant. Cells were washed with PBS and combined with
comet agarose at ratio 1 : 10 and pipetted 75𝜇L/well onto the
OxiSelect Comet Slide.The slide wasmaintained horizontally
and it was transferred to 4∘C in the dark for 15 minutes.
Carefully, the slide was transferred to a container with lysis
buffer (25mL/slide) and was incubated for 30 minutes at 4∘C
in the dark. The lysis buffer was replaced with alkaline solu-
tion (25mL/slide) and was again incubated for 30 minutes
at 4∘C in the dark. The slide was transferred to a horizontal
electrophoresis chamber applying a current setting of 300mA
for 30 minutes. After that, the slide was washed with sterile
milliQ water and water was replaced with cold 70% ethanol
for 5 minutes. Ethanol was removed and slide was allowed
to air dry. Once the agarose and slide were completely dry, it
was added to 100 𝜇L/well of diluted vista green DNA dye and
incubated at room temperature for 15 minutes. Slides were
viewed by epifluorescence microscopy using a FITC filter
(Thornwood, NY).
2.9. Apoptotic Effect of BisBAL Nanoparticles on Erythrocytes.
To analyze if BisBALNPs could lead to apoptosis after incuba-
tion with erythrocytes, the CF 488A/7-AADApoptosis Assay
kit was employed [36]. Following the instructions of provider
(Biotum, Hayward, CA), a confluent monolayer of erythro-
cytes grown with 20𝜇M of BisBAL NPs for 24 hrs was har-
vested and washed with 1x of PBS. After that, cells were resus-
pended with 1x binding buffer and aliquots of 100𝜇L/tube
were made. 5 𝜇L of CF488A-Annexin V and 2 𝜇L of 7-AAD
working solution were added to the cells and incubated at
room temperature for 30 minutes in the dark. Finally, 400𝜇L
of binding buffer was added to each tube and cells were
analyzed by flow cytometry at 488 nm in a flow cytometer BD
Accuri C6 (BD Biosciences, San Jose, CA, USA).
3. Results
3.1. Characterization of BisBAL NPs. Bismuth nanoparticles
obtained were spherical in shape with the number-weighted
average hydrodynamic diameter of 53 nm (Figure 1). The
nanoparticles are composed of rhombohedral crystallites
(≈18 nm) with dithiols as lipophilic surface chemical groups
and the lattice spacing of individual crystallite was 0.325,
which is consistent with nanoscale bismuth nanoparticles
[37]. UV-Vis absorbance measurements revealed that the
nanoparticles had greater (≈70%) affinity towards 1-octanol
rather than water, which further suggests that lipophilic
property of the nanoparticles arises from the dithiols bounds
to nanoparticle surface.
3.2. Morphology of Erythrocytes after Exposition to BisBAL
NPs. In order to determine a possible alteration in the mor-
phology of erythrocytes growing with lipophilic bismuth
nanoparticles, a monolayer of erythrocytes was exposed to
several concentrations of BisBAL NPs (5, 20, 50, 100, and
1000 𝜇M) for 1 hour. After this time, cells were observed find-
ing changes in cell morphology among cells growing with
500 and 1000 𝜇M of BisBAL NPs (Figure 2). These cells were
light refractive and become rounded out of monolayer. In
contrast, cells growing with 5–100 𝜇Mof BisBAL NPs did not
show significant changes in their appearance when they were
compared with cells growing in culture media without any
drug.
3.3. Impact of BisBAL Nanoparticles on Erythrocytes, Leuko-
cytes, and Neutrophils Count and Hemoglobin Level. With
the objective of characterizing in deep the effect of BisBAL
NPs on blood cells, cell viabilityMTT assays and hemoglobin
level were carried out. The results obtained described a little
decrease in the count of blood cells and hemoglobin level
when 50–1000 𝜇M of BisBAL NPs was added to culture cells
for 18 h (Figure 3). The addition of 1% SDS or bulk (1000𝜇M
of bismuth nitrate) reduced cell growing in approximately
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Figure 1: Lipophilic bismuth nanoparticles visualized by scanning electron microscopy.The dominant population of spherical shaped nano-
particles (<100 nm) showing the nanoparticle clusters interspersed among the lesser electron dense materials is shown in the TEM images
(a). (b) Spectrum of elements in the sample observed by SEM.
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Figure 2: Effect of BisBAL nanoparticles on erythrocytes morphology. A monolayer of erythrocytes was obtained from a blood sample in
100𝜇L of minimum essential medium. 50, 100, 500, and 1000 𝜇Mof BisBAL NPs were added to cell culture, incubated for 1 hour at 37∘C with
5% of CO
2
and their influence on erythrocyte culture was observed by optic microscopy using an inverter microscope (Motic, Hong Kong).
The presence of cytopathic effect was identified by amorphous shape and light refractive cells. The bar indicates a size of 50 𝜇m.
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Figure 3: Impact of BisBAL nanoparticles on erythrocytes, leukocytes, and neutrophils count and hemoglobin level. Cell viabilityMTT assays
were performed to determine the influence of 0, 5, 10, 20, 50, 100, 500, and 1000 𝜇Mof BisBALNPs, added to an erythrocytes, leukocytes, and
neutrophils monolayer and incubated for 24 hrs. 1% of SDS was used as positive control and 1000𝜇Mof bismuth nitrate (bulk) was employed
to compare with bismuth nanostructures. After that, the number of erythrocytes, leukocytes, and neutrophils and hemoglobin level were
determined.
50% (Figure 3), showing a clear difference with same con-
centration of the bismuth nanocomposite. The viability did
not change among cells growing with 0–20 𝜇L of BisBAL
NPs with the same results in the level of hemoglobin. All
these results suggest that bismuth nanoparticles did not cause
significant damage on human blood cells in the experimental
conditions analyzed.
3.4. Influence of Bismuth Nanoparticles on Cell Membrane of
Erythrocytes by AM Calcein Assay and Fluorescence Micro-
scopy. Previous results indicated a similar influence of Bis-
BAL NPs on blood cells, which could mean the same target
on this kind of cells. To analyze if plasmatic membrane of
erythrocytes was affected by the presence of bismuth nano-
particles, a monolayer of erythrocytes was incubated with 50,
100, 500, and 1000 𝜇M of BisBAL NPs overnight.
After this, Calcein AM was added which is retained in
the cytoplasm of living cells. When cells were observed by
fluorescent microscopy, Calcein AM was retained only at 50
and 100 𝜇M of BisBAL NPs (Figure 4). In contrast, erythro-
cytes growing with 500 or 1000𝜇M of BisBAL NPs did not
retain the Calcein into their cytoplasm. The same result was
found when red cells were growing with 10% of hydrogen
peroxide (Figure 4). Altogether these results strongly suggest
that plasmatic membrane is affected by interaction with
bismuth nanoparticles at high concentrations.
3.5. BisBAL Nanoparticles on Genomic DNA of Erythrocytes
by Comet Assay and Fluorescence Microscopy. To determine
a possible damage on genomic DNA of erythrocytes by
bismuth nanoparticles, genotoxic assays were developed,
employing the Comet Assay and fluorescencemicroscopy. As
can be seen in Figure 5, after incubation with 1–1000 𝜇M of
BisBAL NPs, the nuclei and indeed the entire cell appeared
to be identical to nontreated cells, suggesting the absence of
toxic effects on genomic DNA of erythrocytes by BisBALNPs
under our experimental conditions. In cells growingwith 10%
of H
2
O
2
the classic stela of a comet was detected (Figure 5)
indicating DNA damage. Based on these results, bismuth
nanoparticles do not seem to affect DNA of host cells.
3.6. Apoptosis Performed by Erythrocytes Growing with Bis-
muth Nanoparticles. Based on last experiments, it was explored
if bismuth nanoparticles could lead to apoptosis of host
cells using the CF 488A/7-AAD Apoptosis Assay kit and
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Figure 4: Influence of bismuth nanoparticles on membrane cell
of erythrocytes by AM Calcein assay and fluorescence microscopy.
Blood cells were treatedwith same techniques described above.After
24 h of incubation, the erythrocytes were stained with AM Calcein
and observed under fluorescence microscopy at 485 and 358 nm
(Thornwood, NY). The images were analyzed by using AxioVision
software (Thornwood, NY). The bar indicates 5 𝜇m.
fluorescence microscopy. The results indicate that BisBAL
nanoparticles at concentrations 500 and 1000 𝜇M promote
apoptosis among erythrocytes (Figure 6). The fluorescent
conjugate of Annexin V interacting with phosphatidylserine
exposed by erythrocytes was clearly observed by fluorescence
microscopy (Figure 6). 7-AAD (7-aminoactinomycin D) is a
membrane-impermeant DNA-binding dye that is excluded
by live cells; as can be seen in Figure 6, it was present in ery-
throcytes growingwith 500 and 1000𝜇Mof BisBALNPs, sug-
gesting their necrotic state. There was no difference between
Analysis of BisBAL NPs on DNA damage of human erythrocytes
BisBAL NPs
100𝜇M 1000𝜇MC− 1𝜇M 10% H2O250𝜇M
Figure 5: BisBALnanoparticles on genomicDNAof erythrocytes by
Comet Assay and fluorescence microscopy. To determine the pos-
sible damage in genomic DNA of erythrocytes after exposition to
BisBAL NPs, Oxiselect Comet Assay was employed. Erythrocytes
were incubated at 37∘C and 5% of CO
2
overnight with 1–1000𝜇M
of BisBAL NPs or 10% H
2
O
2
. Erythrocytes growing only in culture
media were used as negative control (C−). After treatment, blood
cells were analyzed by fluorescence microscopy at 485 nm (Thorn-
wood, NY). The presence of a stela is indicative of DNA damage.
Detection of apoptosis on erythrocytes
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Figure 6: Apoptosis performed by erythrocytes growing with bis-
muth nanoparticles. The possible leading to apoptosis of blood cells
by 100–1000 𝜇M of BisBAL NPs was explored by Annexin V and 7-
AAD assay using fluorescence microscopy at 485 nm (Thornwood,
NY).
100 𝜇M of BisBAL NPs and control (cells growing with only
culturemedia).These results suggest that high concentrations
of bismuth nanoparticles inhibit erythrocytes growth by
altering basic functions and promoting programmed cell
death.
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4. Discussion
In this paper we described the synthesis and characterization
of lipophilic bismuth nanoparticles and their effect on blood
cells. These kinds of nanoparticles have strong antimicrobial
and antibiofilm activities described by our group and others
[5]. However, the lack of strong experimental evidence of
their potential cytotoxicity limits their use in humans. The
toxicological aspects of bismuth compounds are well estab-
lished and the reported side effects include nephropathy, hep-
atitis, encephalopathy, gastroenteritis, and osteoarthropathy
[38–41]. It has been published that bismuth salts cause exten-
sive cytotoxicity on epithelial cells at final concentrations
of 2.5mg/mL [42]. More recently, it was described that bis-
muth nanoparticles are nontoxic at concentration of 0.5 nM.
Nanoparticles at higher concentrations (50 nM) kill 45, 52, 41,
and 34% of HeLa cells for bare nanoparticles, amine termi-
nated bismuth nanoparticles, silica coated bismuth nanopar-
ticles, and polyethylene glycol (PEG) modified bismuth
nanoparticles, respectively [43]. However, our group has
reported no cytotoxic effects onmonkey kidney cells at 2mM
of bismuth oxide nanoparticles after 24 h. In this work, the
presented data shows the influence of lipophilic bismuth
nanoparticles on blood cells. Side effect was not detected
when BisBAL nanoparticles were added to human culture
cells. Tight decreasing was observed in cells count when 50–
1000 𝜇M of BisBAL NPs was added (Figure 3). Hemoglobin
level correlated with blood cells alteration, supporting the
hypothesis of no toxic effects of BisBAL nanoparticles. Pre-
viously, Braun et al. have described that 48 h exposure to
≥500𝜇g/L bismuth stimulated eryptosis promoting apopto-
sis, increasing cytosolic Ca2+ activity and phosphatidylserine
expression on cell surface, decreasing erythrocyte size, and
leading to erythrocyte death [44].This datum correlates with
our finding using 1000 𝜇M of bulk (bismuth nitrate) inhibit-
ing 50% of cell growth (Figure 3). In our results, employing
500 and 1000 𝜇M of BisBAL NPs, the phosphatidylserine
expression on cell surface and decreasing in erythrocyte size
were observed (Figures 2 and 6). Swy et al. described histo-
pathological changes in rats treated with 20mg kg−1 of bis-
muth nanoparticles PGLA encapsulated, including transient
kidney injury and periportal inflammatory process in the
liver [45]. However, ≤100 𝜇M of bismuth nanoparticles did
not cause erythrocytes death, keeping their normal mor-
phology and membrane integrity without leading to apop-
tosis (Figures 2, 4, and 6). This datum is very important
taking into account that early reports indicate that BisBAL
NPs kill pathogenic microorganisms at 0.5–10 𝜇M as final
concentration [5] and compete in efficiency with antibiotics
like vancomycin as broad-spectrum antimicrobial agents [3–
5, 46]. Altogether these results suggest that lipophilic bismuth
nanoparticles could be used in humans without altering
blood cells provided that they were used at final concentra-
tions lower than 100 𝜇M.
The action mechanism of how bismuth or its com-
pounds damage cells is unknown. Early report of Swy et al.
using doses lower than 20mg kg−1 of bismuth nanoparticles
PLGA encapsulated were internalized into cells and remain
into the cytoplasm without side effects [45]. Based on our
experiments with Calcein AM and fluorescence microscopy,
we can argue that in high doses (500–1000𝜇M) BisBAL
nanoparticles enter the cell and stock into cytoplasm of host
cells. The nanoparticles entry will alter the plasmatic mem-
brane permeability of host cells, modifying their homeostasis
and metabolism and finally leading to apoptosis.
5. Conclusions
In summary, lipophilic bismuth nanoparticles (BisBAL NPs)
were not toxic to blood cells at final concentrations lower
than 100 𝜇M. Up to 500𝜇M, BisBAL NPs cause damage
to plasmatic membrane of host cells, thereby leading to
apoptosis or necrosis in the long term.
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